Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 1.00 |
| ▸ | DRD3 | P35462 | 9/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.65 |
| ▸ | DRD4 | P21917 | 6/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.61 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.61 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.56 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.56 |
| ▸ | PLAU | P00749 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29547385 | 1.00 | DRD2 (1.00) | DRD2DRD3ADRA1ADRD4CHRM2 | |
| SCHEMBL29429678 | 1.00 | DRD2 (1.00) | DRD2DRD3ADRA1ADRD4CHRM2 | |
| SCHEMBL43366 | 1.00 | DRD2 (1.00) | DRD2DRD3ADRA1ADRD4CHRM2 | |
| SCHEMBL895845 | 1.00 | DRD2 (1.00) | DRD2DRD3ADRA1ADRD4CHRM2 | |
| Hydrochloric Acid SCHEMBL6824058 | 0.98 | DRD2 (0.97) | DRD2DRD3ADRA1ADRD4CHRM2 | |
| Hydrochloric Acid SCHEMBL31672141 | 0.98 | DRD2 (0.97) | DRD2DRD3ADRA1ADRD4CHRM2 | |
| Hydrochloric Acid SCHEMBL6824054 | 0.98 | DRD2 (0.97) | DRD2DRD3ADRA1ADRD4CHRM2 | |
| Hydrochloric Acid SCHEMBL3468007 | 0.98 | DRD2 (0.97) | DRD2DRD3ADRA1ADRD4CHRM2 | |
| SCHEMBL9315535 | 0.90 | DRD2 (0.82) | DRD2DRD3ADRA1ADRD4CHRM2 | |
| SCHEMBL4210081 | 0.88 | DRD2 (0.79) | DRD2DRD3ADRA1ACHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9879293-B2 | Enzymatic transamination of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20160177354-A1 | ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS | SAFC, INC. | 2016-06-23 | — | — | US | disclosed |
| EP-2462115-B1 | ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS | INFINITY PHARMACEUTICALS INC (US) | 2016-01-06 | — | — | EP | disclosed |
| US-9145353-B2 | Method of preparing (S)-2-amino-5-methoxytetralin hydrochloride | ANHUI KELONG INSTITUTE OF PHARMACEUTICAL (CN) | 2015-09-29 | — | — | US | disclosed |
| US-20140371456-A1 | Enzymatic Transamination of Cyclopamine Analogs | ROYALTY SECURITY, LLC | 2014-12-18 | — | — | US | disclosed |
| US-8703448-B2 | Enzymatic transamination of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20140046095-A1 | Method of Preparing (S)-2-amino-5-Methoxytetralin Hydrochloride | ANHUI KELONG INSTITUTE OF PHARMACEUTICAL (CN) | 2014-02-13 | — | — | US | disclosed |
| US-8236845-B2 | Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-08-07 | — | — | US | disclosed |
| US-8236845-B2 | Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-08-07 | — | — | US | disclosed |
| US-8236845-B2 | Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-08-07 | — | — | US | disclosed |
| EP-2462115-A1 | ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS | Infinity Pharmaceuticals, Inc. (US) | 2012-06-13 | — | — | EP | disclosed |
| US-20120083607-A1 | Enzymatic Transamination of Cyclopamine Analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2012-04-05 | — | — | US | disclosed |
| WO-2011017551-A1 | ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS | INFINITY PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | WO | disclosed |
| US-20100105684-A1 | HETEROCYCLYL-SUBSTITUTED-TETRAHYDRO-NAPHTHALEN-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-04-29 | — | — | US | disclosed |
| US-20100105684-A1 | HETEROCYCLYL-SUBSTITUTED-TETRAHYDRO-NAPHTHALEN-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-04-29 | — | — | US | disclosed |
| US-20100105684-A1 | HETEROCYCLYL-SUBSTITUTED-TETRAHYDRO-NAPHTHALEN-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-04-29 | — | — | US | disclosed |
| EP-2142511-A2 | HETEROCYCLYL-SUBSTITUTED-TETRAHYDRO-NAPHTHALEN-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008116663-A2 | HETEROCYCLYL-SUBSTITUTED-TETRAHYDRO-NAPHTHALEN-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116663-A2 | HETEROCYCLYL-SUBSTITUTED-TETRAHYDRO-NAPHTHALEN-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083607-A1 | Enzymatic Transamination of Cyclopamine Analogs | TKT, TALDO1, BCHE | DRD2 4149/4885DRD3 4061/4885ADRA1A 3775/4885 |
| US-20140046095-A1 | Method of Preparing (S)-2-amino-5-Methoxytetralin Hydrochloride | ADRB2, TPMT, TDO2 | DRD2 44/4885DRD3 143/4885ADRA1A 10/4885 |
| US-20140371456-A1 | Enzymatic Transamination of Cyclopamine Analogs | TKT, TALDO1, BCHE | DRD2 4149/4885DRD3 4061/4885ADRA1A 3775/4885 |
| US-20100105684-A1 | HETEROCYCLYL-SUBSTITUTED-TETRAHYDRO-NAPHTHALEN-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | HNMT, NNT, NQO1 | DRD2 1527/4885DRD3 1739/4885ADRA1A 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.